QuidelOrtho Corporation (QDEL)

Market Cap	877.57M -60.0%
Revenue (ttm)	2.73B -1.9%
Net Income	-1.13B
EPS	-16.69
Shares Out	68.08M
PE Ratio	n/a
Forward PE	5.95
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,707,740
Open	12.69
Previous Close	12.71
Day's Range	12.42 - 13.36
52-Week Range	11.61 - 38.99
Beta	0.92
Analysts	Hold
Price Target	28.25 (+119.16%)
Earnings Date	May 5, 2026

About QDEL

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1979
• Employees: 6,500
• Stock Exchange: NASDAQ
• Ticker Symbol: QDEL
• Website: https://www.quidelortho.com

Financial Performance

In 2025, QuidelOrtho's revenue was $2.73 billion, a decrease of -1.89% compared to the previous year's $2.78 billion. Losses were -$1.13 billion, -44.84% less than in 2024.

Analyst Summary

According to 4 analysts, the average rating for QDEL stock is "Hold." The 12-month stock price target is $28.25, which is an increase of 119.16% from the latest price.

Price Target

$28.25

(119.16% upside)

Analyst Consensus: Hold